Evidence map›Paper›PMID 37919954›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2023

Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer.

Sachin Sharma, Kavya Chandra, Aliva Naik, Anamika Sharma, Ram Sharma, Amandeep Thakur, Ajmer Singh Grewal, Ashwani K Dhingra, Arnab Banerjee, Jing Ping Liou and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Sachin SharmaSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Kavya ChandraDepartment of Biological Sciences, BITS Pilani KK Birla Goa campus, Goa, India.
Aliva NaikDepartment of Biological Sciences, National Institute of Pharmaceutical Education and Research, Hyderabad, India.
Anamika SharmaDepartment of Biological Sciences, National Institute of Pharmaceutical Education and Research, Hyderabad, India.
Ram SharmaSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Amandeep ThakurSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Ajmer Singh GrewalGuru Gobind Singh College of Pharmacy, Yamuna Nagar, India.
Ashwani K DhingraGuru Gobind Singh College of Pharmacy, Yamuna Nagar, India.
Arnab BanerjeeDepartment of Biological Sciences, BITS Pilani KK Birla Goa campus, Goa, India.
Jing Ping LiouSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Santosh Kumar GuruDepartment of Biological Sciences, National Institute of Pharmaceutical Education and Research, Hyderabad, India.
Kunal NepaliSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Taipei Medical University · TWBirla Institute of Technology and Science, Pilani - Goa Campus · INGuru Gobind Singh Medical College and Hospital · INNational Institute of Pharmaceutical Education and Research · INDrug Discovery Laboratory (Norway) · NONational Institute of Pharmaceutical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Structural tailoring of the flavone framework (position 7) via organopalladium-catalyzed C-C bond formation was attempted in this study. The impact of substituents with varied electronic effects (phenyl ring, position 2 of the benzopyran scaffold) on the antitumor properties was also assessed. Resultantly, the efforts yielded a furyl arm bearing benzopyran possessing a 4-fluoro phenyl ring (position 2) (

Indexed as

Antineoplastic AgentsEndometrial NeoplasmsFlavonesApoptosisBenzopyransCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorFemaleHumansPoly(ADP-ribose) Polymerase InhibitorsTubulinTubulin ModulatorsAntineoplastic AgentsBenzopyransFlavonesPoly(ADP-ribose) Polymerase InhibitorsTubulinTubulin Modulatorsbenzopyranendometrial cancerFlavoneinhibitorPARPtubulin

Identifiers

PMID37919954
PMCPMC10627047
OpenAlexW4388298283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.